Meeting
2018 Gastrointestinal Cancers Symposium
Molecular rationale for ERK and EGFR inhibition in colorectal cancer.
Authors
Timothy Joseph Yeatman
Gibbs Cancer Center and Research Institute, Spartanburg, SC
Timothy Joseph Yeatman , Thomas Davis , Mingli Yang , Michael J. Schell , Heiman Wang , Caio Max S. Rocha Lima , Jack Pledger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 679)
DOI
10.1200/JCO.2018.36.4_suppl.679
Abstract #
679
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
First Author: Eiji Shinozaki
Poster
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
First Author: Gargi Dan Basu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2016 ASCO Annual Meeting
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
First Author: Biljana Bazdar-Vinovrski